Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 14, 2020
Daily News
October 14, 2020
- Kyowa CritiCare Resumes Production of Soft Bag Products
October 14, 2020
- Shionogi Chief Says China JV Marks Pivot from Overly US-Focused Investments
October 14, 2020
- Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
- Padcev Shows Positive PII Results for Urothelial Cancer Patients Ineligible for Cisplatin: Astellas
October 14, 2020
- Ono Licenses Epilepsy Med from South Korean Biopharma
October 14, 2020
- J&J Pauses COVID-19 Vaccine Trials, Japan PI Too
October 14, 2020
- Janssen Japan Chief Chris Hourigan Taking Up New Role for APAC
October 14, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…